Valneva inks licensing deal with Elaris for vaccine technology
Austrian biotech firm Elaris FlexCo announced on Wednesday an agreement with Valneva (VALN) to obtain exclusive rights to the technology behind a vaccine candidate for Clostridioides difficile, a bacterium causing diarrhea. The company, founded by two...
Seeking Alpha